Senior Management Led | Transactions

Histogenics

$9,000,000 Series B Preferred Investment From a Group Led by

Exclusive Placement Agent for Histogenics

More Transactions

$175 Million

Has been acquired by

The undersigned acted as exclusive strategic advisor to Peterson Companies, majority shareholder of Propella

Has been acquired by

The undersigned acted as exclusive strategic and financial advisor to ERS

Has been acquired by

The undersigned acted as strategic and financial advisor to Innara Health
Elios

$32 Million

Has Completed a Growth Equity Financing

The undersigned acted as exclusive strategic & financial advisor to ELIOS Vision, Inc.

Contact Us for More Information

Would you like to learn more about working with Outcome Capital or discuss your specific needs?

Contact Us

  • Boston

    20 Custom House St, Suite 1200, Boston, MA 02110
    (617) 431-2278

© Outcome Capital 2024. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.

Business Continuity Plan | Privacy Policy | Regulation Best Interest

Built by Metropolis